L-Arginine for Health & Longevity - Quick Reference Sheet

L-Arginine for Health & Longevity

Created on 07/15/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

L-arginine is an amino acid the body converts into nitric oxide, which relaxes and widens blood vessels. Its most dependable benefit is a modest lowering of blood pressure, with fair support for easing mild erectile difficulty. Other claimed effects are weak or unproven. A low-cost option, real but limited, with a few situations to avoid. (Full Review)

Protocol

Dose
3–6 g/day
Standard for vascular and blood-pressure goals; above ~9 g/day adds side effects without benefit
Schedule
2–3 split doses
Preferred over one large dose to sustain levels and improve gut tolerance
Timing
Pre-exercise 60–90 min
For blood-flow goals; split through the day for blood-pressure goals
Time to effect
Blood pressure
A few weeks
With consistent use
Erectile function
1–3 months
Typical window to judge benefit
Acute blood flow
Within hours
Where present, after a dose

Benefits

Contraindications
  • Recent heart attack (within ~90 days)
  • Advanced kidney impairment (eGFR below ~30)
  • Inherited urea-cycle or arginase disorders
  • Active herpes outbreaks
  • Low baseline blood pressure
  • Pregnancy (except under supervision)
Key Interactions
  • Erectile-dysfunction drugs (sildenafil, tadalafil, vardenafil)
  • Organic nitrates (nitroglycerin, isosorbide dinitrate/mononitrate)
  • Blood-pressure medications (ACE inhibitors, ARBs, calcium channel blockers, beta-blockers, diuretics)
  • Potassium-raising drugs (ACE inhibitors, ARBs, spironolactone)
  • Anticoagulants and antiplatelets (warfarin, aspirin, clopidogrel)
  • Lysine
  • Vasodilating supplements (L-citrulline, dietary nitrate/beetroot, ginkgo, high-dose fish oil)

Risk & Side Effects

  • High: Gastrointestinal distress; additive blood-pressure lowering
  • Medium: Mortality signal after recent heart attack
  • Low: Herpes simplex reactivation; potassium elevation in kidney impairment
  • Speculative: Tumor growth promotion; airway inflammation

Monitoring

Marker Target Why
Blood pressure <120/80 mmHg Primary benefit and over-lowering safety check
Serum potassium 4.0–4.5 mmol/L Detects potassium elevation risk
eGFR >90 mL/min/1.73m² Screens kidney function before and during use
ADMA <0.5 µmol/L Predicts likelihood of response
hs-CRP <1.0 mg/L Tracks vascular inflammation context
Fasting glucose & HbA1c <90 mg/dL; <5.4% Context for metabolic goals
Triglycerides <90 mg/dL Context for any lipid goal

Cadence: Baseline before starting; recheck blood pressure at 4 weeks and 8–12 weeks, then every 6–12 months during continued use; kidney function and potassium on a similar schedule in anyone with kidney concerns.

Qualitative Assessment

  • Energy and exercise capacity: subjective stamina and recovery between efforts
  • Erectile function: firmness and consistency over weeks
  • Symptoms of over-lowering: lightheadedness, dizziness on standing, or fainting
  • Gut tolerance: loose stools and cramping as a guide to dose